Leap Therapeutics Inc (NASDAQ:LPTX)’s traded shares stood at 0.68 million during the last session, with the company’s beta value hitting 0.22. At the close of trading, the stock’s price was $2.55, to imply a decrease of -1.16% or -$0.03 in intraday trading. The LPTX share’s 52-week high remains $4.79, putting it -87.84% down since that peak but still an impressive 34.12% since price per share fell to its 52-week low of $1.68. The company has a valuation of $97.71M, with an average of 0.4 million shares in intraday trading volume over the past 10 days and average of 419.12K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Leap Therapeutics Inc (LPTX), translating to a mean rating of 1.25. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LPTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.38.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
After registering a -1.16% downside in the last session, Leap Therapeutics Inc (LPTX) has traded red over the past five days. The 5-day price performance for the stock is -16.67%, and -15.28% over 30 days. With these gigs, the year-to-date price performance is -11.30%. Short interest in Leap Therapeutics Inc (NASDAQ:LPTX) saw shorts transact 1.01 million shares and set a 2.68 days time to cover.
The extremes give us $5.5 and $5.5 for target low and target high price respectively. As such, LPTX has been trading -115.69% off suggested target high and -115.69% from its likely low.
Leap Therapeutics Inc (LPTX) estimates and forecasts
Looking at statistics comparing Leap Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Leap Therapeutics Inc (LPTX) shares are 20.85% up over the last 6 months, with its year-to-date growth rate higher than industry average at 53.77% against 16.60%.
LPTX Dividends
Leap Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Leap Therapeutics Inc insiders hold 17.29% of total outstanding shares, with institutional holders owning 40.30% of the shares at 48.73% float percentage. In total, 40.30% institutions holds shares in the company.
We also have Simplify Exchange Traded Fds-Health Care ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Leap Therapeutics Inc (LPTX) shares. Going by data provided on Sep 30, 2024 , Simplify Exchange Traded Fds-Health Care ETF holds roughly 1.06 shares. This is just over 2.76% of the total shares, with a market valuation of $2.7 million. Data from the same date shows that the other fund manager holds a little less at 754.74, or 1.97% of the shares, all valued at about 1.92 million.
